BioMerieux Net Income/Loss 2017-2024 | BMXMF
BioMerieux annual/quarterly net income/loss history and growth rate from 2017 to 2024. Net income/loss can be defined as the company's total income or loss before preferred stock dividends, taken from the Income Statement
- BioMerieux net income/loss for the quarter ending December 31, 2024 was $0.460B, a 91.09% increase year-over-year.
- BioMerieux net income/loss for the twelve months ending December 31, 2024 was $1.425B, a 18.17% decline year-over-year.
- BioMerieux annual net income/loss for 2024 was $0.46B, a 31.67% increase from 2023.
- BioMerieux annual net income/loss for 2023 was $0.349B, a 24.72% decline from 2022.
- BioMerieux annual net income/loss for 2022 was $0.464B, a 34.42% decline from 2021.
| BioMerieux Annual Net Income/Loss (Millions of US $) |
|
|---|---|
| 2024 | $460 |
| 2023 | $349 |
| 2022 | $464 |
| 2021 | $708 |
| 2020 | $460 |
| 2019 | $302 |
| 2018 | $302 |
| 2017 | $268 |
| 2016 | $198 |
| 2015 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $15.355B | $4.307B |
| bioM?rieux S.A. designs, develops, manufactures and markets systems in the field of vitro diagnostics. The company provides diagnostic solutions which determine the source of disease and contamination. It also offers solutions for managing infectious diseases, cancers and cardiovascular diseases in clinical applications. The company provides solutions for the enumeration of microbial flora, detection of specific pathogenic bacteria, monitoring of air and surface quality and sterility testing for the agri-food, cosmetics and pharmaceutical industries. bioM?rieux S.A. is based in Marcy L Etoile, France. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $134.174B | 25.17 |
| Elevance Health (ELV) | United States | $86.874B | 11.21 |
| CVS Health (CVS) | United States | $76.179B | 9.47 |
| Cencora (COR) | United States | $56.230B | 19.56 |
| DiDi Global (DIDIY) | China | $23.297B | 35.36 |
| Natera (NTRA) | United States | $20.821B | 0.00 |
| Solventum (SOLV) | United States | $12.571B | 13.31 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.522B | 0.00 |
| CochLear (CHEOY) | Australia | $11.391B | 0.00 |
| Revvity (RVTY) | United States | $10.665B | 18.35 |
| ICON (ICLR) | Ireland | $10.255B | 9.53 |
| Viatris (VTRS) | United States | $9.976B | 3.43 |
| Doximity (DOCS) | United States | $9.570B | 44.57 |
| Avantor (AVTR) | United States | $8.763B | 12.73 |
| HealthEquity (HQY) | United States | $8.657B | 42.59 |
| Medpace Holdings (MEDP) | United States | $8.422B | 22.37 |
| Sonic Healthcare (SKHHY) | Australia | $8.157B | 0.00 |
| Charles River Laboratories (CRL) | United States | $6.660B | 13.05 |
| Amplifon S.p.A (AMFPF) | Italy | $4.966B | 26.21 |
| BrightSpring Health Services (BTSG) | United States | $3.994B | 36.97 |
| Bausch + Lomb (BLCO) | Canada | $3.976B | 23.44 |
| Sotera Health (SHC) | United States | $3.480B | 19.77 |
| Surgery Partners (SGRY) | United States | $2.896B | 37.67 |
| Alignment Healthcare (ALHC) | United States | $2.867B | 0.00 |
| Concentras Parent (CON) | United States | $2.744B | 15.86 |
| Organon (OGN) | United States | $2.259B | 2.40 |
| Ardent Health Partners (ARDT) | United States | $2.117B | 9.02 |
| GeneDx Holdings (WGS) | United States | $1.921B | 73.99 |
| Premier (PINC) | United States | $1.910B | 14.50 |
| Progyny (PGNY) | United States | $1.791B | 39.42 |
| PACS (PACS) | United States | $1.494B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.364B | 27.29 |
| Teladoc Health (TDOC) | United States | $1.211B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.200B | 9.13 |
| Establishment Labs Holdings (ESTA) | $1.066B | 0.00 | |
| Ryman Healthcare (RYHTY) | New Zealand | $0.998B | 0.00 |
| CareDx (CDNA) | United States | $0.953B | 14.88 |
| Agilon Health (AGL) | United States | $0.911B | 0.00 |
| Nutex Health (NUTX) | United States | $0.901B | 13.61 |
| AMN Healthcare Services Inc (AMN) | United States | $0.830B | 7.77 |
| QDM (QDMI) | Hong Kong, SAR China | $0.729B | 0.00 |
| Embecta (EMBC) | United States | $0.614B | 4.14 |
| InnovAge Holding (INNV) | United States | $0.543B | 0.00 |
| LifeMD (LFMD) | United States | $0.523B | 0.00 |
| Enhabit (EHAB) | United States | $0.520B | 42.75 |
| Auna S.A (AUNA) | Luxembourg | $0.505B | 11.37 |
| Sonida Senior Living (SNDA) | United States | $0.465B | 0.00 |
| SBC Medicals (SBC) | United States | $0.398B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.388B | 0.00 |
| Oncology Institute (TOI) | United States | $0.226B | 0.00 |
| Beauty Health (SKIN) | United States | $0.217B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.214B | 0.00 |
| KindlyMD (KDLY) | United States | $0.150B | 0.00 |
| DocGo (DCGO) | United States | $0.137B | 22.33 |
| OncoCyte (OCX) | United States | $0.098B | 0.00 |
| So-Young (SY) | China | $0.088B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.071B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.063B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.057B | 0.00 |
| Biodesix (BDSX) | United States | $0.052B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.040B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.031B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.022B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| ModivCare (MODV) | United States | $0.013B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.009B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.008B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |